Filing Flows › DexCom (DXCM) › Q2 2026 › vs Q1 2026
DexCom (DXCM) Q2 2026 vs Q1 2026 (quarter over quarter)
DexCom's revenue rose $116M (+10%) from $1.2B in Q1 2026 to $1.3B in Q2 2026. Gross margin 63.4% against 62.9% (+0.5 pts).
DexCom, Q2 2026: revenue $1.3B (+13% year over year), operating margin 24.3%, net earnings $249M, operating cash flow $269M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 63.4% | 62.9% | +0.5 pts |
| Operating margin | 24.3% | 21.4% | +2.9 pts |
| Net margin | 19.0% | 16.7% | +2.3 pts |
| Free cash flow margin | 14.1% | 37.7% | -23.6 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.3B | $1.2B | $116M | +10% |
| Gross profit | $830M | $750M | $79.7M | +11% |
| Cost of revenue | $478M | $442M | $36.8M | +8% |
| Operating profit | $318M | $255M | $63.0M | +25% |
| Operating expenses | $512M | $495M | $16.7M | +3% |
| Pre-tax earnings | $318M | $270M | $48.0M | +18% |
| Research & development | $153M | $145M | $7.7M | +5% |
| SG&A | $359M | $350M | $9.0M | +3% |
| Net earnings | $249M | $200M | $49.6M | +25% |
| Income tax | $68.4M | $70.0M | −$1.6M | -2% |
| Depreciation & amortization | $68.2M | $67.1M | $1.1M | +2% |
| Share-based compensation | $39.0M | $43.3M | −$4.3M | -10% |
| Working capital & other | $87.1M | −$216M | $303M | — |
| Operating cash flow | $269M | $526M | −$256M | -49% |
| Free cash flow (OCF − capex) | $184M | $449M | −$264M | -59% |
| Capital expenditures | $84.7M | $76.6M | $8.1M | +11% |
Questions
How much did DexCom's revenue grow quarter over quarter in Q2 2026?
DexCom's revenue rose $116M (+10%) from $1.2B in Q1 2026 to $1.3B in Q2 2026. Gross margin 63.4% against 62.9% (+0.5 pts).